Studies involving multiple aspects of plaque psoriasis evolution, persistence, and progression have produced clues and ...

Johnson & Johnson (J&J) has announced that its dual-acting IL-23 inhibitor Tremfya (guselkumab) has been approved by the ...

Johnson & Johnson has started 2025 better than I expected, even with the long-running talc saga. Find out why I remain ...

From Crohn disease to uncomplicated urinary tract infections and beyond, the FDA issued several high-impact drug approvals ...

Pharma advertisers have kicked off 2025 with a bang, with the top 10 spenders throwing almost 30% more money behind their TV commercials in the first quarter compared to the same period a year ago. | ...

J&J is projecting a $400m hit due to US tariffs in 2025, but reaffirmed its profit outlook while raising its sales forecast.

Johnson & Johnson (NYSE:JNJ), on Tuesday, reported a first-quarter 2025 adjusted EPS of $2.77, up 2.2% year over year, ...

This is a developing news story. Please check back soon for updates. Tremfya reduced signs and symptoms of psoriatic ...

Following the study, the FDA approved the use of Tremfya to treat moderately to severely active ulcerative colitis. In September 2024, the University of Chicago Medicine became the first hospital in ...

For more detail related to the fiscal year 2025 unaudited third quarter results, please visit our web site at www.bioqual.com. Statements herein that are not descriptions of historical facts are ...

Prior to J&J Innovation, Marcella held key roles at Janssen’s Immunology Medical Affairs Department, where she supported the medical engagement, clinical feasibility, and launch strategies for ...